News
ORBUS recieves approval and first purchase order for cefuroxime axetil in Spain
Orbus Pharma Inc., today announces it has received regulatory approval for sale in Spain of the company's generic version of Cefuroxime Axetil Tablets, in 250 mg and 500 mg dosage form.
These dosage forms are equivalent to GlaxoSmithKline's Zinnat(R) (Cefuroxime Axetil) 250mg and 500mg tablets. The Cefuroxime Axetil product will be manufactured at the Orbus Pharma antibiotic plant in Cambridge, Ontario.
Subsequent to regulatory approval in Spain, the company has received the first purchase order from its Spanish marketing partner for finished packs of generic Cefuroxime Axetil Tablets. According to Jeff Renwick, President and CEO, "with this purchase order, we are looking at a significant milestone in the company's entry into the European market for a product that is strategically important to Orbus".
Cefuroxime Axetil tablets are indicated for the treatment of patients with infections caused by susceptible strains of designated organisms in the following diseases: Pharyngitis and Tonsillitis, Lower Respiratory Tract Infections, Urinary Tract Infections and Skin and Skin Structure Infections.
Orbus Pharma Inc., listed on The Toronto Stock Exchange under the symbol ORB, is aggressively pursuing a global strategy of: (1) out-licensing its generic drug developments, using proprietary delivery systems for certain products; and (2) providing contract manufacturing and related services for finished oral dose pharmaceutical products.